Prurigo nodularis: new insights into pathogenesis and novel therapeutics
British Journal of Dermatology · 17.05.2024 · 190 (6) · 798-810
DOI: 10.1093/bjd/ljae052 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Dermatology, online erschienen am 12.02.2024. Verfasst von Viviane Liao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Prurigo. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Lay Summary Prurigo nodularis (PN) is a chronic skin condition featuring extremely itchy nodules on the skin of the legs, arms and trunk of the body. PN affects approximately 72 per 100 000 people and the severe itch associated with the condition can negatively impact a person’s sleep, work and social life. However, the cause of PN remains unclear. Current understanding of PN is based on imbalances in the immune system leading to widespread inflammation as well as dysregulation of the nerves in the skin. Immune molecules released from T cells [such as interleukin (IL)-4, -13, -31, -17, -22 and -31] increase systemic inflammation and are elevated in people with PN. Activated inflammatory cells (such as mast cells or eosinophils) may also release factors that promote inflammation, itch and neural changes within the skin. Neural dysregulation in PN features a lower density of itch-sensing nerve fibres in the epidermis (upper layer of the skin) and a higher density of itch-sensing nerve fibres in the dermis (lower layer of the skin). Because the pathogenesis of PN is not fully understood, the therapies available for PN have had limited success in reducing itch and nodules. The only drug currently approved for PN in the USA and Europe is dupilumab, an IL-4Rα inhibitor that blocks signalling through IL-4 and IL-13, which is undergoing post-marketing surveillance. Other new drugs are being assessed in various phases of clinical trials, including nemolizumab, vixarelimab, barzolvolimab, ruxolitinib, abrocitinib, povorcitinib and nalbuphine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Dermatology.
- Maryland Itch Center, University of Maryland School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Viviane Liao, Hannah L Cornman, Emily Ma, Shawn G Kwatra
Förderung
- NIAMS NIH HHS
- NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institutes of Health
Zitieren
APA
Liao, V., Cornman, H. L., Ma, E., & Kwatra, S. G. (2024). Prurigo nodularis: new insights into pathogenesis and novel therapeutics. British Journal of Dermatology, 190(6), 798-810. https://doi.org/10.1093/bjd/ljae052
Vancouver
Liao V, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. British Journal of Dermatology. 2024;190(6):798-810. doi:10.1093/bjd/ljae052
BibTeX
@article{Liao2024,
author = {Liao, Viviane and Cornman, Hannah L and Ma, Emily and Kwatra, Shawn G},
title = {Prurigo nodularis: new insights into pathogenesis and novel therapeutics},
journal = {British Journal of Dermatology},
year = {2024},
volume = {190},
number = {6},
pages = {798--810},
doi = {10.1093/bjd/ljae052}
}
EUVIMED